Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077796 | 0.85 | MAPK1 (0.37) | LMNACYP2C9TSHRBLMPPARA | |
| SCHEMBL8018805 | 0.80 | APLNR (0.32) | CYP2C9MEN1KMT2AAPLNR | |
| SCHEMBL7567670 | 0.78 | BTK (0.37) | BTKMAPK1MEN1KMT2AAPLNR | |
| SCHEMBL3675536 | 0.76 | MAPK1 (0.33) | LMNACYP2C9TSHRBLMPPARA | |
| SCHEMBL19585884 | 0.76 | BTK (0.35) | BTKCYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL8466617 | 0.74 | DGAT1 (0.38) | DGAT1MAPK1MEN1KMT2A | |
| SCHEMBL9018584 | 0.72 | GRM4 (0.41) | LMNACYP2C9TSHRMEN1KMT2A | |
| SCHEMBL1706674 | 0.69 | MAPK1 (0.40) | LMNACYP2C9TSHRBLMPPARA | |
| SCHEMBL7099129 | 0.69 | ALDH1A1 (0.47) | BTKLMNACYP2C9TSHRMEN1 | |
| SCHEMBL7219863 | 0.69 | ALDH1A1 (0.47) | BTKLMNACYP2C9TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731499-B1 | PROCESS FOR PRODUCING 1,2-CIS-2-FLUOROCYCLOPROPANE-1-CARBOXYLIC ESTER COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| CN-1930112-B | Process for producing 1,2-cis-2-fluorocyclopropane-1carboxylic esters | DAIICHI SEIYAKU CO | 2010-06-23 | — | — | CN | disclosed |
| US-7381833-B2 | Process for producing 1,2-cis-2-fluorocyclopropane-1-carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2007-08-16 | — | — | US | disclosed |
| US-7199260-B2 | Process for reductive dehalogenation | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| CN-1930112-A | Process for producing 1,2-cis-2-fluorocyclopropane-1carboxylic ester compound | DAIICHI SEIYAKU CO (JP) | 2007-03-14 | — | — | CN | disclosed |
| EP-1731499-A1 | PROCESS FOR PRODUCING 1,2-CIS-2-FLUOROCYCLOPROPANE-1CARBOXYLIC ESTER COMPOUND | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-20060052626-A1 | Process for reductive dehaloganation | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1582513-A1 | PROCESS FOR REDUCTIVE DEHALOGENATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | HACL2, B2M, CA1 | BTK 2532/4885LMNA 1302/4885CYP2C9 1932/4885 |
| US-20060052626-A1 | Process for reductive dehaloganation | IDUA, CYP2F1, DEK | BTK 3334/4885LMNA 2835/4885CYP2C9 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.